Endometrial cancer: guideline history
2 dated versions from 2021 to 2024 listing 3 changes. Pick two versions to see what changed between them; the timeline below shows every version with the event it is anchored to.
- RecategorisedAdvanced or recurrent, first lineCheckpoint inhibitor plus carboplatin-paclitaxel becomes the preferred first-line regimen, first for dMMR then for all patients.carboplatin-paclitaxel alone carboplatin-paclitaxel plus dostarlimab, pembrolizumab or durvalumab (category 1)
Timeline
Anchored to: FDA approvals of dostarlimab for dMMR recurrent disease (April 2021, GARNET) and full approval of lenvatinib plus pembrolizumab (July 2021, KEYNOTE-775)
- addedRecurrent, dMMR, after platinum: Dostarlimab (or pembrolizumab) for mismatch-repair-deficient disease.
- addedRecurrent, pMMR, after platinum: Lenvatinib plus pembrolizumab as the preferred regimen for mismatch-repair-proficient disease.
Anchored to: FDA approvals of dostarlimab with carboplatin-paclitaxel for dMMR disease (July 2023, RUBY), pembrolizumab with carboplatin-paclitaxel (June 2024, NRG-GY018), durvalumab with chemotherapy for dMMR (June 2024, DUO-E) and dostarlimab for all comers (August 2024)
- recategorisedAdvanced or recurrent, first line: Checkpoint inhibitor plus carboplatin-paclitaxel becomes the preferred first-line regimen, first for dMMR then for all patients.carboplatin-paclitaxel alone → carboplatin-paclitaxel plus dostarlimab, pembrolizumab or durvalumab (category 1)
Where the bodies stand today
| Setting and intervention | NCCN | ESMO | NICE | ASCO | Verdict |
|---|---|---|---|---|---|
Endometrial cancer · Advanced or recurrent, dMMR, first line Dostarlimab with carboplatin-paclitaxel (RUBY) | Preferred Category 1, preferred 2023-07 | Recommended I, A 2024 | Recommended 2024 | · | Bodies agree |
Other cancers
Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.